Inspire Medical Systems, Inc. (INSP) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-13
Business type: Asset play
How it makes money
It sells its implantable neurostimulation system primarily to hospitals and ambulatory surgery centers, driving revenue when physicians perform obstructive sleep apnea procedures.
Although its promotional efforts target patients and referring physicians to build demand, the direct purchasers of the system are the hospitals and ambulatory surgery centers where the surgical procedures take place. These facilities purchase the equipment and are subsequently reimbursed by third-party payors, including commercial insurers and government programs like Medicare.
Sales volume depends heavily on the willingness of insurers to maintain positive coverage policies and the ability of patients to navigate prior authorization requirements. Additionally, sales experience seasonal patterns, often rising in the fourth quarter as patients meet their annual insurance deductibles, and dipping in the first quarter when deductibles reset and out-of-pocket costs rise.
What protects it: the moat
It relies on regulatory approvals, proprietary closed-loop technology, and extensive clinical data, though management notes the ongoing risk of losing market acceptance.
The company protects its market position through regulatory clearances, including premarket approval from the FDA, European Union MDR certification, and approvals from Japanese authorities. It also cites a substantial body of peer-reviewed clinical data, including publications in major medical journals, supporting the safety and efficacy of its neurostimulation therapy.
Despite these barriers, management notes that as a single-product company, any failure to maintain physician and patient demand or satisfy market expectations would directly harm its business, since virtually all revenue depends on the success of the Inspire system.
What could damage it
Unfavorable changes in third-party reimbursement policies or coding confusion could restrict patient access, reducing hospital purchases and permanently impairing earnings.
Hospitals and ambulatory surgery centers rely on third-party payors and specific CPT billing codes to secure reimbursement for implanting the device. If commercial insurers or Medicare administrative contractors alter coverage policies, introduce restrictive prior authorization hurdles, or generate persistent coding confusion, healthcare facilities may curtail procedures. Because the company depends almost entirely on sales of this single system, a sustained drop in facility purchases driven by reimbursement barriers would directly impair its revenue and profitability.
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.